1-7 of 7
Jim Growcott
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.

Sarah A. Loddick, Sandra Brave, Hayley Campbell, Luke Gaughan, Jim Growcott, Natalie Lahan, Elizabeth Mouchet, Daniel O'Neill, Craig Robson, Fadhel Shaheen, Andrew Thomason, Dawn Trueman, Graeme Walker, Nigel Brooks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B107.
https://doi.org/10.1158/1535-7163.TARG-11-B107
Published: 12 November 2011
View article titled, Abstract B107: Characterization of a small molecule selective androgen receptor downregulator: A novel approach for the treatment of castration-resistant prostate cancer.
Journal Articles

Abstract C130: Plucked human scalp hairs: Potential utility as a surrogate tissue for the assessment of therapies targeting the androgen receptor

Jim Growcott, Ged Brady, Karen Pickering, Jill Walker, Susan Lovick, Raj Chetty, Helen Kevill, Manoj Prahladan, Emma Grimes, Elliott Harrison, Timothy Mefo, Darren Hodgson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C130.
https://doi.org/10.1158/1535-7163.TARG-09-C130
Published: 10 December 2009
View article titled, Abstract C130: Plucked human scalp hairs: Potential utility as a surrogate tissue for the assessment of therapies targeting the androgen receptor
Journal Articles

Abstract C9: Utility of serological apoptosis biomarkers: Assessment in a phase II study of zibotentan (ZD4054) in patients with hormone‐resistant prostate cancer

Mike Malone, Helen Mann, Jim Growcott, Fouziah Butt, David Moore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C9.
https://doi.org/10.1158/1535-7163.TARG-09-C9
Published: 10 December 2009
View article titled, Abstract C9: Utility of serological apoptosis biomarkers: Assessment in a phase II study of zibotentan (ZD4054) in patients with hormone‐resistant prostate cancer
Journal Articles

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Catherine Geh, Sandra Oakes, Clive Green, Mike Walker, Nicholas Newcombe, Stephen Green, Jim Growcott, Andy Barker, Robert W. Wilkinson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1856–1866.
https://doi.org/10.1158/1535-7163.MCT-08-0836
Published: 14 July 2009
View article titled, AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts
Open the PDF for AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts in another window
Includes: Supplementary data
Journal Articles

Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity

Jeffrey Cummings, Cassandra Hodgkinson, Rajesh Odedra, Patrizia Sini, Simon P. Heaton, Kirsten E. Mundt, Tim H. Ward, Robert W. Wilkinson, Jim Growcott, Andrew Hughes, Caroline Dive
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 455–463.
https://doi.org/10.1158/1535-7163.MCT-07-2136
Published: 17 March 2008
View article titled, Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity
Open the PDF for Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity in another window
Journal Articles

Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents

Beth Pflug, Kevin McHugh, Jason D'Antonio, Elena Bocola-Mavar, Jon Curwen, Jim Growcott, Joel Nelson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A287.
Published: 01 November 2007
View article titled, Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents
Journal Articles

The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis

Elizabeth Williams, Erik Thompson, Dhanya Sreedharan, Nigel Brooks, Jon Curwen, Jim Growcott
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A271.
Published: 01 November 2007
View article titled, The combination of the specific endothelin A receptor antagonist ZD4054 and submaximal bisphosphonate pamidronate prevents soft-tissue metastasis